Centrosomes are the major sites for microtubule nucleation in mammalian cells, although both chromatin-and kinetochore-mediated microtubule nucleation have been observed during spindle assembly. As yet, it is still unclear whether these pathways are co-regulated and the molecular requirements for microtubule nucleation at kinetochore are not fully understood. This work demonstrates that kinetochores are initial sites for microtubule nucleation during spindle reassembly after nocodazole. This process requires local RanGTP accumulation concomitant with delocalization from kinetochores of the hydrolysis factor RanGAP1. Kinetochore-driven microtubule nucleation is also activated after cold-induced microtubule disassembly when centrosome nucleation is impaired, e.g. after Polo-like kinase 1 depletion, indicating that dominant centrosome activity normally masks the kinetochore-driven pathway. In cells with unperturbed centrosome nucleation, defective RanGAP1 recruitment at kinetochores after treatment with the 
INTRODUCTION
It is now clear that mitotic spindle assembly can occur via different pathways (for reviews see Gadde and Heald 2004; Wadsworth and Khodjakov, 2004; Rieder, 2005, O' Connel and Khodjakov, 2007) . In most somatic cell types, centrosomes nucleate microtubules (MTs) to build a mitotic spindle. Functional spindles also form in cells lacking centrosomes, e.g. in higher plants and some animal oocytes. In Xenopus eggs, spindles assemble through MT nucleation from chromatin in a process requiring the GTPase Ran (Carazo-Salas et al., 1999; Kalab et al., 1999) which, in its GTP-bound form, is generated near chromatin under the localized action of the nucleotide exchange factor RCC1 (Moore et al., 2002; Li et al., 2003; Chen et al., 2007) . In the Xenopus system, RanGTP releases spindle assembly factors containing NLS signals, such as NuMa and TPX2 (Gruss et al., 2001; Nachury et al., 2001; Wiese et al., 2001) , from the inhibitory binding to importin α/β, in the immediate vicinity of chromatin, thus promoting nucleation of MTs therein (reviewed by Weis, 2003; Ciciarello et al., 2007) . This has led to propose that spindle formation in acentrosomal cells depends on a gradient of RanGTP, concentrating around chromosomes and diluting away from them (Caudron et al., 2005; Kalab et al., 2006) . Local activity of RanGTP and importin α/β also contribute to spindle assembly in centrosome-driven cells (Nachury et al., 2001; Ciciarello et al., 2004 , Kalab et al., 2006 . In these cells, chromatin-associated MT nucleation is normally suppressed by the dominant centrosome activity, yet remains an intrinsic potential that can be resumed under certain circumstances, as a functional spindle still form when centrosomes are removed by laser ablation (Khodjakov et al., 2000) , or centrosome activity is abolished by specific mutations (Bonaccorsi et al., 1998) .
Kinetochores were also reported to direct MT nucleation in mammalian cells after spindle disrupting drugs, but this idea was subsequently questioned, based on concerns for possible artifactual effects of the drugs (Rieder, 2005 and references therein). More recently, in vivo imaging of mitosis has shown that unattached kinetochores facing away from centrosomes can promote the formation of MTs during mitotic spindle assembly in both mammalian (Khodjakov et al., 2003) and Drosophila cells (Maiato et al., 2004) . In both cases, chromosome arms shielded the distal kinetochore from interaction with microtubules generated at centrosomes, possibly providing time for kinetochore nucleation to occur. However, the importance of this kinetochore-driven MT nucleation for spindle assembly in centrosome-containing cells is not clearly defined, as only a few examples were recorded in the live cells studies (Khodjakov et al., 2003; Maiato et al., 2004) .
Furthermore, the molecular requirements for MT formation at kinetochore are not fully understood.
Recently, Tulu et al. (2006) observed microtubule formation at Bub1-positive sites after release from nocodazole (NOC)-induced spindle disassembly in live cell imaging experiments (Tulu et al., 2006) . Formation of MT foci in the chromatin region was severely inhibited when the activity of the Ran-dependent spindle assembly factor TPX2 was suppressed by either microinjection of excess importin β, or by direct TPX2 depletion (Tulu et al., 2006) . These results suggest that the dissociation of import complexes entrapping NLS-bearing spindle assembly factors contributes to the genesis of MT foci. However, the limited resolution of current live cell imaging methods did not allow discriminating whether the inhibition of extracentrosomal MT foci reflected the suppression of RanGTP-dependent MT nucleation specifically at kinetochores or, rather, a disruption of the overall RanGTP gradient, which is generated along the entire chromosome region by the persisting binding of RCC1 to mitotic chromatin. Furthermore, it remains to be determined what localizes extracentrosomal MT nucleation to the kinetochore area, given that the exchange factor for Ran is distributed along the entire length of the chromosome. We have re-addressed these questions by assessing mitotic spindle re-assembly after microtubule depolymerization by nocodazole or after cold-induced spindle disassembly in cells with impaired centrosome-nucleating activity. We now report that the localized accumulation of RanGTP at kinetochores is responsible for MT nucleation therein. The complex between RanGTP, the export receptor Crm1 and NES-bearing proteins modulates MT nucleation at kinetochores.
MATERIALS AND METHODS

Cell cultures and treatments
Human lung diploid fibroblasts (MRC-5 cells) and human osteosarcoma U2OS cells were obtained from the American Type Culture Collection (Rockville, MD) and maintained in Minimum Essential Medium supplemented with 10 % fetal calf serum, antibiotics, L-glutamine, non-essential aminoacids and Hepes. Cells were grown at 37°C, in a humidified atmosphere, with 5% CO 2 .
MRC5 or U2OS cultures were treated with 1.5 μM NOC for 16 hours to completely disassembly MTs. tsBN2 cells (a gift of M.Dasso) were grown at 32°C and received 4 μM NOC for 3 hours either at 32°C or at 39°C. At the end of the NOC incubation, cells were washed three times in prewarmed medium, re-incubated in fresh medium to release the mitotic block and fixed at the indicated times after NOC release. For MT regrowth after ice-induced depolymerization, U2OS cells were incubated for 60 minutes on ice, prewarmed media was then added and cells were incubated at 37°C for the indicated times. When needed, 20 nM leptomycin B was added to culture medium 2 h before incubation on ice.
RNAi experiments
Small interfering RNA (siRNA) oligonucleotides targeting Plk1 or firefly luciferase gene sequences (GL2) were from Qiagen. SiRNAs were mostly used at the final concentration of 80 nM using oligofectamine (Invitrogen) as transfection reagent. SiRNA sequences and conditions of interference were described (De Luca et al., 2006) . All analyses were performed 40 h from transfection.
Immunoblotting
An equal number of cells from tsBN2 cultures grown to 85% confluence at 32° C, or shifted to 39°C during the last 4 h of culture, was pelleted by centrifugation for 10 min at 1500 rpm and washed in phosphate-buffered saline (PBS). Cells were extracted with RIPA buffer (50 mM TrisHCl pH 8.0, 150 mM NaCl, 1%, NP40, 1 mM EGTA, 0.25% sodium deoxycholate) supplemented with 1 μg/ml Leupeptin, 1 μg/ml Pepstatin, 1 μg/ml Aprotinin, 1 mM PMSF, 1 mM DTT, 1 mM NaVO 4 and 1 mM NaF. Proteins were resolved by electrophoresis on a 10% SDS-polyacrylamide gel, and transferred to a nitrocellulose membrane (Whatman Schleicher & Schuell PROTRAN) using a semi-dry blotting system (BIO-RAD) in transfer buffer (48 mM Tris, 39 mM Glycin, 0,037% SDS and 20% Methanol). 60 μg of extract per lane were loaded. Blocking and antibody incubations were in 5% low-fat dry milk in TBS (10 mM TrisHCl pH 8, 150 mM NaCl) containing 0,1% Tween 20. Membranes were blocked for 30 min, primary antibodies were incubated for 1 h, secondary antibodies for 30 min, at RT. Primary antibodies were anti-RCC1 (Santa Cruz Biotechnology, 0,5μg/ml) and anti-RanBP1 (Santa Cruz Biotechnology, 0,5μg/ml). U2OS cells were lysed, resolved and transferred under similar conditions. 40 μg of extract per lane were loaded.
Primary antibodies were mouse anti-α-tubulin (ascite fluid, clone B-5-1-2, Sigma, 1:2000) and mouse anti-Plk1 (ab 14210, Abcam,1μg/ml).
Immunostaining
Cells were rinsed in PHEM buffer (60 mM Pipes, 25 mM Hepes, pH 6.9, 10 mM EGTA, 4 mM was still lacking in previous live cell studies (Tulu et al., 2006) that left out the possibility that association of MT to kinetochores was successive to MT nucleation around chromatin. These results, together with those of Tulu et al. (Tulu et al., 2006) , identify kinetochores as the initial sites for MT nucleation after NOC-induced spindle reassembly.
Localized accumulation of RanGTP at kinetochores promotes MT nucleation
To get some insight into the molecular requirements for MT nucleation at kinetochores we analysed several regulators of microtubule nucleation during spindle reassembly after NOC. We initially wondered whether NOC displaced regulators of MT nucleation from centrosomes to chromosomes and whether that did in turn promote kinetochore-dependent MT nucleation. We found that both Aurora-A and Plk1 kinases maintained their localization to centrosomes (Aurora-A, Plk1) and kinetochores (Plk1), with no variation during NOC treatment (Supplemental Figure 3) , ruling out the possibility that NOC impaired the association of these crucial regulators with centrosomes and that this in turn activated nucleation from kinetochores.
We next investigated Ran, which is clearly required for MT nucleation from chromatin in oocytes and in mammalian cells (reviewed in Ciciarello et al., 2007) and has been implicated in the kinetochore pathway after NOC (Tulu et al., 2006) . To directly investigate the requirement for RanGTP in the kinetochore nucleation pathway, we made use of tsBN2 cells, a baby hamster kidney-derived conditional cell line harbouring a mutant version of the chromatin-bound exchange factor RCC1 that is degraded at the non-permissive temperature (Ohtsubo et al., 1989) . To further substantiate the requirement for RanGTP at kinetochores in MT nucleation, we decided to directly visualize the intracellular localization of RanGTP both during NOC exposure and after drug removal. This was achieved by using of a conformational antibody that specifically reacts with the GTP-bound form of Ran (Richards et al., 1995) . That antibody had been previously employed to reveal RanGTP at centrosomes and along spindle MTs in mitotic human cells (Keryer et al., 2003; Tedeschi et al., 2007) . The specificity of the antibody for the GTP-bound form of Ran in mitosis was further demonstrated by the weak antibody reactivity on the mitotic spindle when the RCC1 exchange factor was inactivated in tsBN2 cells (Supplemental Figure 4) . Next, we carried out RanGTP localization to kinetochores was still seen at early stages of MT formation at kinetochores, when short MTs appeared from kinetochores ( Figure 3A , 45" release); at later release times, when
MTs emanated from most kinetochores, the RanGTP signal still persisted at kinetochores although with a clearly decreased intensity ( Figure 3A , 5' release). Measuring the RanGTP signal intensity and normalizing to the CREST signal confirmed the partial loss of RanGTP from kinetochores at late recovery time (0.32 ± 0.04 vs 0.13 ± 0.02 at 0 and 5' recovery, respectively; > 40 centromeres from 6-8 cells per experimental point, Figure 3C ). The temporal pattern of RanGTP at kinetochores
suggests that RanGTP accumulation is locally required prior to the onset of MT nucleation at kinetochores, transiently persists at kinetochores in the earliest stages of MT formation and is eventually followed by dissociation from kinetochores and/or hydrolysis therein.
RanGTP levels are regulated by the counteracting activities of the chromatin-associated nucleotide exchange factor RCC1 and the cytoplasmic GTP-hydrolyzing factor RanGAP1. During mitosis, RanGAP1 is targeted at kinetochores in a SUMO-conjugated form together with the Ranbinding protein RanBP2, which has SUMO-ligase activity (Joseph et al., 2002) . RanGAP1/RanBP2 recruitment at kinetochores is stabilized by its association in a complex containing RanGTP and Crm1, the export receptor for NES-bearing cargoes .
In light of the ability of RanGAP1 to activate GTP hydrolysis on Ran and to localize at kinetochores in mitosis, we reasoned that the kinetochore accumulation of RanGTP after NOC might have been associated with a decrease in RanGAP1 concentration therein. In metaphase cells from control cultures, RanGAP1clearly localized at kinetochores ( Figure 3B , DMSO), as previously reported (Joseph et al., 2002) . At opposite with this defined localization pattern, no preferential RanGAP1 accumulation was observed during NOC exposure, such that the GTP-hydrolysis factor was completely absent from kinetochores both after MT depolymerization ( Figure 3B , time 0, see insect, quantification in Figure 3D ) and when MTs began to reform at kinetochores immediately after NOC release ( Figure 3B , 45"). RanGAP1 was again observed at kinetochores after several minutes of NOC release, when plus ends of MTs anchored at the centrosome reached kinetochores in prometa/metaphase cells ( Figure 3B , 15' and Figure 3D ). On the whole, these findings identify the accumulation of the GTP-bound form of Ran as a prerequisite for MT nucleation at kinetochores and demonstrate that NOC-dependent delocalization of RanGAP1 and accumulation of RanGTP is responsible for this localized nucleation.
Centrosome impairment stimulates kinetochore nucleation.
We next asked whether mammalian cells can activate MT nucleation from kinetochores independently of MT-targeting drug treatments. Polo-like kinase 1 (Plk1) is a major centrosomal kinase with key roles in centrosome maturation and spindle assembly (Barr et al., 2004) ; its inactivation impairs γ−tubulin recruitment at centrosomes (Sumara et al., 2004; van Vugt et al., 2004) producing defective MT regrowth after cold treatment in U2OS cells (De Luca et al., 2006) .
We therefore employed Plk1-specific small interfering (si) RNA to down-regulate the nucleating capacity of centrosomes and assess whether the kinetochore-associated MT nucleation pathway would be favoured. We interfered U2OS cells with control GL2 or Plk1-specific siRNAs and Accordingly, the capacity of centrosomes to develop a nucleating aster was decreased in Plk1-silenced compared to GL2 cells ( Figure 4A , 65", compare GL2 vs. Plk1-). However, kinetochore nucleated MTs do not elongate much since their minus ends are captured by MTs nucleated by neighbour kinetochores ( Figure 4A , 65", compare microtubule length in centrosome-nucleated MTs in GL2 cells and kinetochore-nucleated MTs in Plk1-cells). These results suggest that nucleation from centrosomes and kinetochores are negatively interrelated, providing new ground for the hypothesis that the two pathways compete for a common supply of tubulin dimers. During a normal mitosis, the high rate of microtubule growth at nucleating asters may depress the capacity of kinetochores to efficiently form MTs.
Crm1/RanGTP/RanGAP1 complex regulates MT nucleation at kinetochores
Mitotic RanGTP acts through its interaction with two major effectors: importin β, which regulates NLS-containing spindle assembly factors, and the export receptor for NES proteins,
Crm1. In association with Crm1, RanGTP is required to assemble a ternary complex with NES factors (Fornerod et al., 1997) , including RanGAP1-RanBP2 . In mitotic cells, the Crm1/RanGTP/RanGAP1-RanBP2 complex localizes at kinetochores, where it contributes to regulate the spindle checkpoint activity (Arnaoutov and Dasso, 2003) and K-fiber stability . Given that NOC-induced nucleation from kinetochores delocalized RanGAP1, we wondered whether the kinetochore-associated Crm1/RanGTP/RanGAP1-RanBP2 ternary complex also regulates MT nucleation from kinetochores. To address this question, we performed cold-induced depolymeryzation and MT-regrowth assays in the presence of leptomycin B (LMB), a Crm1-specific drug that has been shown to inhibit the formation of the ternary complex between Crm1, RanGTP and NES proteins (Fornerod et al., 1997; Petosa et al., 2004) . We found that RanGAP1 was displaced from kinetochores of U2OS cells after 3 hours of LMB treatment ( Figure 5A ), consistent with a requirement of CRM1 and RanGTP for stable recruitment of RanGAP1 to kinetochores . When U2OS cells were exposed to cold and then rewarmed to allow MT depolymerization and regrowth, MTs appeared at centrosomes ( Figure   5 , B and C,-LMB), consistent with the centrosomal pathway predominantly activated after ice.
When cultures were treated with LMB to inhibit RanGAP1 localization at kinetochores prior to ice incubation, and then MT were depolymerised by cold treatment, a fraction of cells activated MT nucleation from kinetochores as early as 45" after rewarming, and subsequently formed extracentrosomal α tubulin foci ( Figure 5 , B and C,+LMB). Accordingly, in these cells RanGAP1 was undetectable on kinetochores during MT regrowth ( Figure 5B , +LMB). Interestingly, kinetochore nucleation was achieved in the presence of an intact MT assembly activity of the centrosomes, which developed large nucleating asters upon rewarming ( Figure 5B , +LMB). This set of data demonstrates that the Crm1/RanGTP/RanGAP1 complex at kinetochores suppresses kinetochore MT nucleation during spindle assembly in somatic cells, and that inhibiting the formation of this complex can re-activate this spindle assembly pathway.
HURP is required for MT stabilization at kinetochores
Having demonstrated that a localized accumulation of RanGTP is required to activate MT nucleation from kinetochores, we then moved to search RanGTP-regulated factors that may act as downstream effectors of RanGTP function in kinetochore nucleation. Most RanGTP regulated MTnucleating factors, and notably TPX2, are transported by minus-end directed motors towards centrosomes, where they are activated by RanGTP association with importin β and consequent release of nucleating factors from importin β/α inhibitory activity. HURP (hepatoma upregulated protein) is a Ran-regulated factor that localizes along kinetochore microtubules in the vicinity of chromosomes (Koffa et al., 2006; Wong and Fang, 2006) in a RanGTP dependent manner (Sillje et al., 2006) . In accordance with its potential role as downstream effector for RanGTP in the vicinity of chromatin, HURP has been shown to stabilize kinetochore MTs and contribute to MT stabilization of both centrosome-and chromatin-nucleated MTs (Koffa et al., 2006; Sillje et al., 2006; Wong and Fang, 2006) . This prompted us to investigate whether HURP was also involved in regulating kinetochore MT nucleation during MT regrowth both after NOC and following cold induced MT disassembly. When MTs were depolymerized by NOC, HURP was diffuse in the mitotic nucleocytoplasm ( Figure 6A , NOC), consistent with this protein being a MT-binding protein (Sillje et al., 2006) . HURP, however, clearly colocalized with tubulin at kinetochores after NOC release, both on kinetochore tubulin spots and on short MTs in between kinetochores ( Figure   6A , NOC release, see inset). Similarly, kinetochores were devoid of tubulin and HURP after coldinduced MT depolymerization in both GL2-and Plk1-depleted cells ( Figure 6B , GL2 on ice, Plk1-on ice), but HURP concentrated along short MTs protruding from kinetochores in Plk1-silenced cells during rewarming, with a clear accumulation at the kinetochore-MT interface ( Figure 6B , Plk1-, rewarming, inset). These results demonstrate that nucleation of MTs from kinetochores is promptly followed by association of HURP to the nascent MTs. They further suggest that MT plus ends are localized at kinetochores and are stabilized by HURP association.
DISCUSSION
The present work demonstrates that the Ran GTPase network regulates the formation of MTs from kinetochores in mammalian cells. Our study uncovers a specific mechanism that regulates RanGTP production at kinetochores and is responsible for the formation of MTs from kinetochores. Analysis of MT regrowth in tsBN2 cells demonstrated that RanGTP production specifically at kinetochores, in addition to its formation around chromatin, is required for extracentrosomal MT nucleation in mammalian cells. In addition, the use of a RanGTP specific antibody after MT disassembly identified the accumulation of the GTP-bound form of Ran as a prerequisite for MT nucleation at kinetochores. Thereafter, nucleation at kinetochores was followed by the association to the kinetochore-nucleated MTs of the Ran-regulated protein HURP, which stabilized their growth.
Recent work has demonstrated that a fraction of Ran localizes during mitosis to kinetochores in a complex with the export receptor Crm1 and the RanGAP1/RanBP2 subcomplex; this complex is proposed to work in an auto-regulatory loop in which Crm1, in association with RanGTP, is required to localize the RanGAP1-RanBP2 subcomplex, which in turn promotes RanGTP hydrolysis and therefore catalyzes its own release from the kinetochores (reviewed by . The effects of disrupting this auto-regulatory loop, by either RCC1 inactivation, or by LMB treatment, indicate that the complex functions in maintaining the spindle assembly checkpoint active (Arnaoutov and Dasso, 2003) and in the formation of mature kinetochore fibres in metaphase .The present data extend the range of events controlled by the kinetochore-associated Ran network. We have detected GTP-bound Ran at kinetochores prior to the onset of MT nucleation from these sites in NOC-treated cells. The absence of MTs inhibits RanGAP1 accumulation at kinetochores (this work and Joseph et al., 2002) , providing a mechanism whereby the self-regulatory loop that normally regulates nucleotide turnover on Ran is disrupted and RanGTP is allowed to accumulate at kinetochores. Inhibition of
Crm1 by LMB did also result in the failure to localize RanGAP1 to kinetochores and in the activation of MT nucleation in conditions that otherwise would not allow nucleation from kinetochores, i.e. after cold. These results demonstrate that the RanGTP/Crm1/RanGAP1 complex controls MT formation from kinetochores: an unbalance within the self-regulatory loop towards RanGTP accumulation, either by NOC treatment or through LMB exposure, promotes kinetochore nucleation. Finally, we also show that GTP hydrolysis on Ran does not take place during kinetochore-driven MT nucleation, since RanGAP1, the hydrolysis factor for RanGTP, relocalizes to kinetochores only after K fibres are present. The time-course analysis with conformational antibody reported here shows that RanGTP is present at kinetochores during the initial stages of MT regrowth, when kinetochore-mediated MT nucleation is highly active, but then its concentration gradually decreases, suggesting that it possibly dissociates from the kinetochores after activation of MT nucleation and becomes hydrolyzed.
On the basis of our findings, we would like to propose the following model for the role of the Ran network in MT nucleation at kinetochores (Figure 7 ). Both Crm1 and Ran localize at kinetochores, where the latter is loaded with GTP by chromatin-bound RCC1; this sets the potential for forming ternary complexes with NES-containing kinetochore proteins. When, in a normal mitosis, MTs capture kinetochores, RanGAP1 is loaded on kinetochores and, therein, can become part of the complex with RanGTP and Crm1: when this occurs, RanGTP hydrolysis is triggered in the complex and RanGDP is released from the kinetochores (Figure 7, left) . A similar autoregulatory Ran "loop", based on RanGAP1 recruitment at kinetochores and subsequent RanGTP hydrolysis, regulates kinetochore fiber structure and spindle checkpoint timing at the meta-toanaphase transition . In the absence of MTs, such as during NOC 
